Osteoarthritis, HipPhase 2NCT01113762
Metal-metal Articulations Versus Standard 28 mm Cementless Total Hip Arthroplasty
A Phase 2 study testing articular surface replacement ASR, DePuy, ReCap/Magnum modular head, Biomet and Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet in people with Osteoarthritis, Hip, run by University of Southern Denmark at 2 sites in Denmark.
Trial summary
Younger hip patients often need revision of their hip replacement due to wear and loosening. Newer concepts (resurfacing and large head total hip replacement) with articulation surfaces in metal may reduce the wear, increase the longevity of the implant and give an improved function. Read more about this study
- Who is it for?
- Ages 40 to 65 years
- Conditions the study is for
- Osteoarthritis, Hip
- What is being tested?
- articular surface replacement ASR, DePuy, ReCap/Magnum modular head, Biomet and Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 71 participants
- Where
- 2 sitesDenmark
- Study dates
- Feb 2007to Nov 2019
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Primary hip osteoarthritis
- Secondary osteoarthritis due to mild dysplasia
- Age from 40 to 65 years
Who cannot join
- Dysplasia with CE angle < 25 degrees on the AP projection
- Severe femoral head deformation
- Reduced femoral neck length
- Leg length discrepancy more than 1 cm
- Need for restoration of offset
- Deformation after fractures or earlier osteotomies
Show all 18Show fewer
- A previous hip arthroplasty
- Inflammatory arthritis
- Endocrinological disease with bone metabolic manifestations
- Renal disease
- Malignant disease
- Neuro/muscular or vascular diseases of the affected leg
- Osteoporosis
- Use of opioid pain killers due to other diseases
- High dose corticosteroids
- Obese with BMI > 35
- Pregnant or planning to be
- Ppresented problems that would prevent completing our follow-up program
Trial locations and contacts
2 sites in 1 country.
Denmark2 sites
Naestved Hospital Dept. of orthop. surg.
Næstved, 4700
Odense University hospital
Odense, 5000
About this study
Official title: Metal-metal Articulations vs Standard 28 mm Cementless Total Hip Arthroplasty in Younger Patients. Randomized Studies
Younger hip patients often need revision of their hip replacement due to wear and loosening. Newer concepts (resurfacing and large head total hip replacement) with articulation surfaces in metal may reduce the wear, increase the longevity of the implant and give an improved function. The possible downside is that these concepts releases metal debris to the body. The investigators wish to see if the newer interventions are a clinical improvement compared to standard. The investigators also wish to investigate the extent of metal released to the body and any effect on the immune system. Finally the investigators wish to investigate the stability of these new implants and their ability to preserve the bone around the implant.
The investigators hypothesis is:
That the metal on metal articulations will not have better clinical outcomes than standard The resurfacing implant is expected to preserve the bone of the upper femoral bone. The implants are expected to be stabile within the first year.
- Conditions
- Osteoarthritis, Hip
- Being tested
- articular surface replacement ASR, DePuy, ReCap/Magnum modular head, Biomet, Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet, 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)
- Keywords
- Arthroplasty, Replacement, Hip, Bone Density, Rehabilitation, T-Lymphocytes, Chromium Alloys
- Medical subject headings
- Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
articular surface replacement ASR, DePuyDevice
posterolateral incision
ReCap/Magnum modular head, BiometDevice
posterolateral incision
Bimetric stem, mallory/head cup, 28 mm ceramic head, BiometDevice
posterolateral incision
28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)Device
posterolateral incision
| Study group | Role | What they receive |
|---|---|---|
| resurfacing | Experimental | a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint Receives: Device: articular surface replacement ASR, DePuy |
| large head THA | Experimental | a standard stemmed THA but with a large metal head, and a metal-metal articulation Receives: Device: ReCap/Magnum modular head, Biomet |
| 28 mm ceramics-polyethylene | Active comparator | a standard 28 mm head uncemented THA Receives: Device: Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet |
| 28 mm metal-polyethylene THA | Active comparator | a standard stemmed uncemented THA Receives: Device: 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Range of motion
range of motion in the hip joint evaluated by goniometer
Measured: Up to two months before surgery
Range of motion
Range of motion of the hip joint
Measured: 8 weeks +/- 1 week
Range of motion
range of motion in the hip joint
Measured: 6 months +/- 2 weeks
Range of motion
range of motion in the hip joint
Measured: 1 year +/- 1 month
range of motion
range of motion in the hip joint
Measured: 2 year +/- 1 month
Secondary outcomes (53)
Metal ions
Crome and cobalt ions in serum and whole blood.
Measured: Up to two months before surgery
BMD
bone mass density around the implants
Measured: Within the first week following surgery
RSA
radiostereommetry. Measurement of micromotions (subsidence, rotation and translations)of the implant in relation to the bone
Measured: Within the first week following surgery
HHS
Harris hip score. An investigator asssesed hip questionnaire including pain, function, deformities and range of motion
Measured: Up to two months before surgery
UCLA activity
University of California Los Angeles activity score. A score over the intensity of activities the patient engages in.
Measured: Up to two months before surgery
WOMAC
patient reported outcome of pain, stifness and disability during activities of daily living.
Measured: Up to two months before surgery
EQ-5d
a short quality of life measure. patient reported
Measured: Up to two months before surgery
T cell count
quantitative analysis of the level of T-cells in the blood
Measured: Up to two months before surgery
X-ray
an assesment of the placement of the metal cup. Inclination and anteversion.
Measured: within 2 years of surgery
steps
using a pedometer 1 week prior to each check up the annual step rate is calculated
Measured: Up to two months before surgery
sick leave
an assesment of the rehabilitation period following the intervention
Measured: assesed 6 months following surgery.
Metal ions
Crom and cobalt
Measured: 8 weeks +/- 1 week
Metal ions
Crome and cobalt
Measured: 6 months +/- 2 weeks
Metal ions
crome and cobalt
Measured: 1 year +/- 1 month
metal ions
crome and cobalt
Measured: 2 year +/- 1 month
BMD
bone mass desity around the implant
Measured: 8 weeks +/- 1 week
BMD
Bone mass density around the implant
Measured: 1 year +/- 1 month
BMD
Bone mass density around the implant
Measured: 2 year +/- 1 month
RSA
Radiostereometry of implant
Measured: 8 weeks +/- 1 week
RSA
Radiostereometry of implant
Measured: 6 months +/- 2 weeks
RSA
Radiostereometry of implant
Measured: 1 year +/- 1 month
RSA
Radiostereometry of implant
Measured: 2 year +/- 1 month
HHS
Harris hip score
Measured: 8 weeks +/- 1 week
HHS
Harris hip score
Measured: 6 months +/- 2 weeks
HHS
Harris hip score
Measured: 1 year +/- 1 month
HHS
Harris hip score
Measured: 2 years +/- 1 month
UCLA activity
activity score
Measured: 8 weeks +/- 1 week
UCLA activity
activity score
Measured: 6 months +/- 2 weeks
UCLA activity
activity score
Measured: 1 year +/- 1 month
UCLA activity
activity score
Measured: 2 years +/- 1 month
WOMAC
self reported function
Measured: 3 weeks
WOMAC
self reported function
Measured: 6 weeks
WOMAC
self reported function
Measured: 8 weeks +/- 1 week
WOMAC
self reported function
Measured: 6 months +/- 2 weeks
WOMAC
self reported function
Measured: 1 year +/- 1 month
WOMAC
self reported function
Measured: 2 years +/- 1 month
EQ-5d
quality of life
Measured: 8 weeks +/- 1 week
EQ-5d
quality of life
Measured: 6 months +/- 2 weeks
EQ-5d
quality of life
Measured: 1 year +/- 1 month
EQ-5d
quality of life
Measured: 2 years +/- 1 month
T cell count
T cell count
Measured: 8 weeks +/- 1 week
T cell count
T cell count
Measured: 6 months +/- 2 weeks
T cell count
T cell count
Measured: 1 year +/- 1 month
T cell count
T cell count
Measured: 2 years +/- 1 month
steps
steps measured by pedometer during the week prior to check up
Measured: 8 weeks +/- 1 week
steps
steps measured by pedometer during the week prior to check up
Measured: 6 months +/- 2 weeks
steps
steps measured by pedometer during the week prior to check up
Measured: 1 year +/- 1 month
steps
steps measured by pedometer during the week prior to check up
Measured: 2 years +/- 1 month
blood loss
blood loss measured in mL
Measured: during surgery
days in hospital
days in hospital following surgery
Measured: from admission to discharge from hospital
complications
surgery and implant related complications
Measured: within the first 2 years following surgery
surgery time
time from skin is incised to skin is closed
Measured: during surgery
incision length
the length of the surgical incision in cm
Measured: during surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Apr 2010 (estimated)
- Study startFeb 2007
- Primary completionNov 2009
- Study completionNov 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Osteoarthritis, HipStudies of the same condition, open and under way.
- More trials run by University of Southern DenmarkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 71 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Southern Denmark
- Sponsor type
- University, hospital or other
- Collaborators
- Ministry of the Interior and Health, Denmark, Region Zealand, Zimmer Biomet, DePuy Orthopaedics
- Responsible party
- Principal investigator, jeannette ostergaard penny, University of Southern Denmark
- Investigators
- Soeren Overgaard, MD, professor, phd, Principal investigator, University of Southern Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01113762
- Sponsor's protocol ID
- VF20050133
- Status last verified
- Dec 2017
- First submitted
- 28 Apr 2010
- Last updated
- 19 Dec 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Penny JO, Varmarken JE, Ovesen O, Nielsen C, Overgaard S. Metal ion levels and lymphocyte counts: ASR hip resurfacing prosthesis vs. standard THA: 2-year results from a randomized study. Acta Orthop. 2013 Apr;84(2):130-7. doi: 10.3109/17453674.2013.784657.
PubMed 23597114Penny JO, Ovesen O, Varmarken JE, Overgaard S. Similar range of motion and function after resurfacing large-head or standard total hip arthroplasty. Acta Orthop. 2013 Jun;84(3):246-53. doi: 10.3109/17453674.2013.788435. Epub 2013 Mar 26.
PubMed 23530872Nissen T, Douw K, Overgaard S. Patient-reported outcome of hip resurfacing arthroplasty and standard total hip replacement after short-term follow-up. Dan Med Bull. 2011 Oct;58(10):A4310.
PubMed 21975150
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metal-metal Articulations vs Standard 28 mm Cementless Total Hip Arthroplasty in Younger Patients. Randomized Studies
- ClinicalTrials.gov ID
- NCT01113762
- Acronym / sponsor ID
- VF20050133
- Conditions
- Osteoarthritis, Hip
- Keywords
- Arthroplasty, Replacement, Hip, Bone Density, Rehabilitation, T-Lymphocytes, Chromium Alloys
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 71 participants (actual)
- Lead sponsor
- University of Southern DenmarkUniversity, hospital or other
- Collaborators
- Ministry of the Interior and Health, Denmark, Region Zealand, Zimmer Biomet, DePuy Orthopaedics
- Study start
- Feb 2007
- Primary completion
- Nov 2009 (actual)
- Study completion
- Nov 2019 (estimated)
- First posted
- 30 Apr 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Younger hip patients often need revision of their hip replacement due to wear and loosening. Newer concepts (resurfacing and large head total hip replacement) with articulation surfaces in metal may reduce the wear, increase the longevity of the implant and give an improved function. The possible downside is that these concepts releases metal debris to the body. The investigators wish to see if the newer interventions are a clinical improvement compared to standard. The investigators also wish to investigate the extent of metal released to the body and any effect on the immune system. Finally the investigators wish to investigate the stability of these new implants and their ability to preserve the bone around the implant.
The investigators hypothesis is:
That the metal on metal articulations will not have better clinical outcomes than standard The resurfacing implant is expected to preserve the bone of the upper femoral bone. The implants are expected to be stabile within the first year.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| resurfacing | Experimental | Device: articular surface replacement ASR, DePuya hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint |
| large head THA | Experimental | Device: ReCap/Magnum modular head, Biometa standard stemmed THA but with a large metal head, and a metal-metal articulation |
| 28 mm ceramics-polyethylene | Active comparator | Device: Bimetric stem, mallory/head cup, 28 mm ceramic head, Biometa standard 28 mm head uncemented THA |
| 28 mm metal-polyethylene THA | Active comparator | Device: 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)a standard stemmed uncemented THA |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Primary hip osteoarthritis
- Secondary osteoarthritis due to mild dysplasia
- Age from 40 to 65 years
Key exclusion criteria (18 listed)
- Dysplasia with CE angle < 25 degrees on the AP projection
- Severe femoral head deformation
- Reduced femoral neck length
- Leg length discrepancy more than 1 cm
- Need for restoration of offset
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| articular surface replacement ASR, DePuyposterolateral incision | Device | resurfacing |
| ReCap/Magnum modular head, Biometposterolateral incision | Device | large head THA |
| Bimetric stem, mallory/head cup, 28 mm ceramic head, Biometposterolateral incision | Device | 28 mm ceramics-polyethylene |
| 28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)posterolateral incision | Device | 28 mm metal-polyethylene THA |
Primary outcome
Range of motion
Time frame: Up to two months before surgery
range of motion in the hip joint evaluated by goniometer
Range of motion
Time frame: 8 weeks +/- 1 week
Range of motion of the hip joint
Range of motion
Time frame: 6 months +/- 2 weeks
range of motion in the hip joint
Range of motion
Time frame: 1 year +/- 1 month
range of motion in the hip joint
range of motion
Time frame: 2 year +/- 1 month
range of motion in the hip joint
53 secondary outcomes
Metal ions
Time frame: Up to two months before surgery
BMD
Time frame: Within the first week following surgery
RSA
Time frame: Within the first week following surgery
HHS
Time frame: Up to two months before surgery
UCLA activity
Time frame: Up to two months before surgery
WOMAC
Time frame: Up to two months before surgery
EQ-5d
Time frame: Up to two months before surgery
T cell count
Time frame: Up to two months before surgery
X-ray
Time frame: within 2 years of surgery
steps
Time frame: Up to two months before surgery
sick leave
Time frame: assesed 6 months following surgery.
Metal ions
Time frame: 8 weeks +/- 1 week
Metal ions
Time frame: 6 months +/- 2 weeks
Metal ions
Time frame: 1 year +/- 1 month
metal ions
Time frame: 2 year +/- 1 month
BMD
Time frame: 8 weeks +/- 1 week
BMD
Time frame: 1 year +/- 1 month
BMD
Time frame: 2 year +/- 1 month
RSA
Time frame: 8 weeks +/- 1 week
RSA
Time frame: 6 months +/- 2 weeks
RSA
Time frame: 1 year +/- 1 month
RSA
Time frame: 2 year +/- 1 month
HHS
Time frame: 8 weeks +/- 1 week
HHS
Time frame: 6 months +/- 2 weeks
HHS
Time frame: 1 year +/- 1 month
HHS
Time frame: 2 years +/- 1 month
UCLA activity
Time frame: 8 weeks +/- 1 week
UCLA activity
Time frame: 6 months +/- 2 weeks
UCLA activity
Time frame: 1 year +/- 1 month
UCLA activity
Time frame: 2 years +/- 1 month
WOMAC
Time frame: 3 weeks
WOMAC
Time frame: 6 weeks
WOMAC
Time frame: 8 weeks +/- 1 week
WOMAC
Time frame: 6 months +/- 2 weeks
WOMAC
Time frame: 1 year +/- 1 month
WOMAC
Time frame: 2 years +/- 1 month
EQ-5d
Time frame: 8 weeks +/- 1 week
EQ-5d
Time frame: 6 months +/- 2 weeks
EQ-5d
Time frame: 1 year +/- 1 month
EQ-5d
Time frame: 2 years +/- 1 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2017.
- Derived from this study: PubMed 23597114Penny JO, Varmarken JE, Ovesen O, Nielsen C, Overgaard S. Metal ion levels and lymphocyte counts: ASR hip resurfacing prosthesis vs. standard THA: 2-year results from a randomized study. Acta Orthop. 2013 Apr;84(2):130-7. doi: 10.3109/17453674.2013.784657.
- Derived from this study: PubMed 23530872Penny JO, Ovesen O, Varmarken JE, Overgaard S. Similar range of motion and function after resurfacing large-head or standard total hip arthroplasty. Acta Orthop. 2013 Jun;84(3):246-53. doi: 10.3109/17453674.2013.788435. Epub 2013 Mar 26.
- Derived from this study: PubMed 21975150Nissen T, Douw K, Overgaard S. Patient-reported outcome of hip resurfacing arthroplasty and standard total hip replacement after short-term follow-up. Dan Med Bull. 2011 Oct;58(10):A4310.
Related trials for Osteoarthritis, Hip
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Recruiting
Effects of EDUcation and EXercise Compared to Education Alone on Clinical and Physiological Outcomes in Patients With Hip Osteoarthritis
Hip Osteoarthritis
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Soeren Overgaard, MD, professor, phd principal investigator
University of Southern Denmark
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing articular surface replacement ASR, DePuy, ReCap/Magnum modular head, Biomet and Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet in people with Osteoarthritis, Hip, run by University of Southern Denmark at 2 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Dec 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Range of motion (time frame: Up to two months before surgery). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01113762, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2017.